Navigation Links
BeyondSpring's Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Date:2/21/2017

NEW YORK, Feb. 21, 2017 /PRNewswire/ -- BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data from its Phase 2 trial of BeyondSpring's innovative lead asset, Plinabulin, for the treatment of non-small cell lung cancer (NSCLC) with Docetaxel has been selected for oral presentation at this year's ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Fla.

Dr. Alain Mita, M.D., Associate Professor of Medicine and Co-Director, Experimental Therapeutics, at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, will present the findings during Oral Abstract Session A on February 23, 2017, at 1 p.m. ET at the Hyatt Regency Orlando.

The Phase 2 data shows that, in NSCLC patients with a measurable lung lesion, the combination of Plinabulin with Docetaxel increases median overall survival by 4.6 months, versus treating with Docetaxel alone. The addition of Plinabulin to Docetaxel also shows a statistically significant improvement in duration of response, which is indicative of Plinabulin's immune effects, versus Docetaxel alone (P<0.05). The addition of Plinabulin to Docetaxel also mitigates the known Docetaxel-related safety concerns, such as Neutropenia, without increasing immune-related adverse events.

"The Phase 2 data with Plinabulin in combination with Docetaxel is very encouraging and provides a strong justification for the global Phase 3 trial with the Plinabulin-Docetaxel combination in patients with at least one measurable NSCLC lesion, which is now underway globally," said Dr. Mita.

"Plinabulin is targeting critical steps in the immune-cascade, independent from that of PD-1 / PD-L1 intervention," added Dr. Ramon Mohanlal, BeyondSpring Chief Medical Officer. "Published data shows that Docetaxel monotherapy has a slight advantage over PD-1 inhibitors in PD-L1-negative NSCLC patients. Given the safety concerns with Docetaxel, such as Neutropenia, adding Plinabulin to Docetaxel not only improves overall efficacy but also mitigates Docetaxel-induced Neutropenia. The Plinabulin-Docetaxel combination may represent a highly effective, safe and cost-effective alternative to Nivolumab, in particular with PD-L1-negative NSCLC."

"This new data represents an important milestone for BeyondSpring, because it demonstrates Plinabulin's continued effectiveness at treating NSCLC and its potential to revolutionize cancer treatment as we know it today for patients in need all over the world," concluded Dr. Lan Huang, BeyondSpring CEO. "Combined with Plinabulin's equally high potential to be an efficient, cost-effective treatment for Neutropenia prevention, BeyondSpring is making significant strides with Plinabulin overall, pushing forward with our goal to set the standard when it comes to innovative cancer treatments in the months and years to come."

The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium will take place on February 23 through 25. BeyondSpring's global Phase 3 NSCLC trial in patients with a measurable lung lesion is also actively recruiting in the U.S.

About BeyondSpring Pharmaceuticals
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring has advanced its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer. The Company is also planning a Phase 2/3 clinical trial for Plinabulin in the prevention of chemotherapy-induced Neutropenia. BeyondSpring's experienced management team brought a combined 30+ drugs to market.

About Plinabulin
Plinabulin is an innovative small molecule agent that has multiple mechanisms of action, with an immune-enhancing mechanism and tumor vasculature targeting and activating JNK pathway to induce cancer cell apoptosis.

CONTACT INFO:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
ckasunich@kcsa.com / asingh@kcsa.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beyondsprings-promising-clinical-data-for-lead-asset-on-non-small-cell-lung-cancer-treatment-selected-for-presentation-at-2017-asco-sitc-clinical-immuno-oncology-symposium-300410946.html


'/>"/>
SOURCE BeyondSpring Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
2. Novan Announces Promising Results of SB204 Clinical Study
3. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
4. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
5. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
6. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
7. Cancer Experts Meet in Boston to Discuss a Promising Approach to Treating the Disease
8. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
9. Boehringer Ingelheims interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
10. Actinobac Biomed Founder Receives Two Awards For Promising New Drug
11. Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2019)... (PRWEB) , ... April 19, 2019 , ... Want to ... MD with Advanced Dermatology PC , “but we still have work to do ... can be.” , The evidence is overwhelming: According to the American Academy of Dermatology, ...
(Date:4/19/2019)... Ohio (PRWEB) , ... April 18, 2019 , ... ... top CBD sales for 4/20 weekend 2019 . The list contains the best sales ... This weekend, many CBD companies will offer deep discounts on popular items. And CBD ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... Association (FMA). The FMA is one of the country’s premier professional associations dedicated ... Medicine in Florida. The FMA currently represents over 25,000 members on issues of ...
Breaking Medicine Technology:
(Date:4/18/2019)... ... April 18, 2019 , ... BNCT is a ... targeted radiation to cancer cells while sparing surrounding healthy tissue. NTI’s unique and ... from the ground up for high reliability and ease of maintenance, NTI’s platform ...
(Date:4/18/2019)... HILLS, Calif. (PRWEB) , ... April 18, 2019 ... ... an upscale dental practice in Beverly Hills that offers a full menu of ... superior cosmetic treatments and sought-after expertise in biomimetic dentistry, which relies on minimally-invasive ...
(Date:4/18/2019)... , ... April 18, 2019 , ... ... its first ever Cannabis Industry Report . The study—which considers consumers’ perceptions ... intersections with retail and manufacturing, offering insight into what kinds of products consumers ...
(Date:4/17/2019)... (PRWEB) , ... April 17, 2019 , ... ... SHIN SUNG TK, a Korean company located in Gwangju, Korea, and has highly ... its own patent. The two companies were in discussion of a potential partnership ...
(Date:4/17/2019)... ... , ... On May 3, Kyle Marcelli will return to Mid-Ohio SportsCar ... Continental Tire SportsCar Challenge race in 2018, Kyle Marcelli and Nate ... #60 KohR Motorsports / Roush Performance Ford Mustang GT4 across the finish ...
Breaking Medicine News(10 mins):